Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Share-based Compensation: 2013-2024

Historic Share-based Compensation for Collegium Pharmaceutical (COLL) over the last 12 years, with Dec 2024 value amounting to $32.4 million.

  • Collegium Pharmaceutical's Share-based Compensation rose 34.09% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 24.97%. This contributed to the annual value of $32.4 million for FY2024, which is 19.40% up from last year.
  • As of FY2024, Collegium Pharmaceutical's Share-based Compensation stood at $32.4 million, which was up 19.40% from $27.1 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Share-based Compensation ranged from a high of $32.4 million in FY2024 and a low of $21.9 million during FY2020.
  • Over the past 3 years, Collegium Pharmaceutical's median Share-based Compensation value was $27.1 million (recorded in 2023), while the average stood at $27.5 million.
  • In the last 5 years, Collegium Pharmaceutical's Share-based Compensation soared by 32.56% in 2020 and then decreased by 5.69% in 2022.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Share-based Compensation stood at $21.9 million in 2020, then grew by 10.70% to $24.3 million in 2021, then dropped by 5.69% to $22.9 million in 2022, then rose by 18.63% to $27.1 million in 2023, then increased by 19.40% to $32.4 million in 2024.